18F-氟昔洛韦检出前列腺癌复发后的挽救治疗
该研究回顾本机构2017至2018年18F-氟昔洛韦PET/CT检出复发的28例前列腺癌患者,分析其治疗模式与肿瘤学结局。所有患者接受挽救治疗后PSA均下降,作者认为18F-氟昔洛韦PET/CT可定位复发且后续挽救治疗似乎有效,需更长随访判断能否改善生存。
要点
- 18F-氟昔洛韦PET/CT可定位前列腺癌复发灶,本组28例中局部复发6例、盆腔淋巴结9例、远处淋巴结9例、骨转移4例。
- 术后复发者至PET/CT中位时间67个月(中位PSA 1.63 ng/mL),放疗后复发者95个月(中位PSA 13.31 ng/mL)。
- 所有患者挽救治疗后PSA均下降,但需更长随访判断能否改善生存。
核心结论
- 18F-氟昔洛韦PET/CT可定位前列腺癌复发,后续挽救治疗似乎有效且PSA下降;更长随访将揭示这些诊断检查及后续治疗能否改善前列腺癌生存。
研究设计与样本
- 回顾本机构2017至2018年18F-氟昔洛韦PET/CT检出复发、既往接受根治性治疗的前列腺癌男性患者,分析治疗模式与肿瘤学结局,共28例。
主要发现
- 28例中23例初始接受手术、其中13例另接受术后放疗,5例初始接受根治性放疗。
- 术后至PET/CT中位时间67个月(中位PSA 1.63 ng/mL),放疗后至PET/CT中位时间95个月(中位PSA 13.31 ng/mL)。
- 复发部位为局部6例、盆腔淋巴结9例、远处淋巴结9例、骨转移4例。
- 初始手术者中4例接受挽救放疗、3例接受雄激素剥夺治疗(ADT);初始手术加术后放疗者中3例接受挽救性盆腔淋巴结清扫、4例接受挽救放疗、2例接受ADT;初始放疗者中4例接受挽救ADT。
- 所有患者挽救治疗后PSA均下降。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: F-Fluciclovine is the most recent prostate cancer (PCa)-directed PET radiotracer approved by the US Food and Drug Administration for detection of recurrent PCa. We report the treatments and outcomes of patients at our institution with PCa recurrences detected on F-fluciclovine PET/CT. METHODS: We identified men with recurrent PCa detected on F-fluciclovine PET/CT performed between 2017 and 2018 who were previously treated definitively and analyzed their patterns of care and cancer-specific outcomes. RESULTS: We identified 28 men with recurrent PCa detected on F-fluciclovine PET/CT. Twenty-three were initially treated with surgery and 13 also received postoperative radiation therapy (RT). Five patients were initially treated with definitive radiation. After surgery, the median time to F-fluciclovine PET/CT was 67 months (median prostate-specific antigen [PSA] of 1.63 ng/mL). After RT, the median time to F-fluciclovine PET/CT was 95 months with median PSA of 13.31 ng/mL. Six men recurred locally, 9 recurred in the pelvic nodes, 9 had distant nodal recurrences, and 4 had osseous metastases. Of the patients initially treated with surgery, 4 received salvage radiation and 3 received androgen deprivation therapy (ADT). Of the patients initially treated with surgery and postoperative RT, 3 received salvage pelvic nodal dissection, 4 received salvage radiation, and 2 received ADT. Of the patients initially treated with radiation, 4 received salvage ADT. All had PSA decline after salvage therapy. CONCLUSIONS: F-fluciclovine PET/CT can localize PCa recurrences, and subsequent salvage therapies appear effective with decreasing PSA. Longer follow-up will reveal if these diagnostic tests and subsequent therapies will improve PCa survival.
引用
- Hwang L, Paluch J, Jadvar H, et al. Salvage Therapies After 18F-Fluciclovine Detected Prostate Cancer Recurrences. Clin Nucl Med. 2020. PMID: 32520496. doi:10.1097/RLU.0000000000003104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。